Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials after an earlier setback, boosting optimism the shot may join the fight against the pandemic this year.
from Section Page News - Modern Healthcare https://ift.tt/3eShr33
No comments:
Post a Comment